

(b) Development of a registration and licensing system under which no drug product would be permitted in interstate commerce unless produced under quality control standards set by the Secretary of Health, Education, and Welfare. (P. 48)

(c) Limitation of free drug samples to those specifically requested by prescribers, by industry agreement or legislation. (P. 48)

(d) Development of more effective methods for ascertaining actual acquisition costs of prescription drugs. (P. 48)

4. The Secretary of Health, Education, and Welfare should call for a joint study by the Department of Health, Education, and Welfare, the Department of Commerce, the Department of Justice, the Federal Trade Commission, and other Federal agencies to consider--

(a) The substantial differences in the prices at which drug products are offered to community pharmacies and to hospitals and government agencies. (P. 49)